Vonoprazan fumarate is a Potassium-Competitive Acid Blocker (P-CAB). It suppresses basal and stimulated gastric acid secretion at the secretory surface of the gastric parietal cell by inhibiting the H + /K+ ATPase enzyme system in a potassium-competitive manner. It does not require activation by acid. Vonoprazan may selectively concentrate in the parietal cells in both the resting and stimulated states. It binds to the active proton pumps in a non-covalent and reversible manner.
Vonoprazan is usually used to treat gastric/duodenal ulcers, reflux esophagitis, and for suppression of recurrence of gastric ulcers & duodenal ulcers associated with low-dose aspirin or nonsteroidal anti-inflammatory drug, medication in combination with clarithromycin and amoxicillin for the eradication of Helicobacter pylori.
© 2024. Aristopharma Ltd. All rights reserved.